Abstract
Context: Cardiac arrest occurs due to excess strain of the heart which results in retrenchment of its structure were by thickens nerve walls and increases cholesterol. Recently, valsartan (angiotensin-2 receptor antagonists) stays successful over various groups of patients. Commonly these attacks are prone to occur in the early morning hours so there is a need of delivering required drugs appropriately at required time and required place. Objective: Therefore our main objective of the present work is to develop sustained release tablets of valsartan which would be effective for 24 hr from the time of administration. Parallel studies were conducted between three different techniques of formulation methods to reveal the role and nature of different excipients and methods employed in the release profile. Materials and methods: Hydroxypropyl methyl cellulose 15cps was used as granulating agent in the range of 10 to 35 mg to optimize the release. The role of Sodium starch glycolate was also studied by incorporating it in the range of 8-12.5 mg. Results and conclusion: The optimized formulation followed both diffusion and erosion mechanism in all cases according to Korsmeyer's equation drug release. The formulation would be worthy in large scale production as its consumption of production time and materials involved are very less which plays effective role in the market value when compared with other methods. The comparative valsartan release studies revealed that the release rate was dependant on the polymers relative amounts, the technique used to prepare the tablets, and the absence or presence of the SSG. It is evident from the results that sustained release tablet prepared with HPMC and a hydrophobic disintegrating agent (SSG, 5% w/w) is a better system for once-daily sustained release of a drug like valsartan. The tablets made were found to satisfy the compendial requirements of hardness and friability. Invivo study demonstrated that the investigated sustained-release matrix tablet was capable of maintaining constant plasma valsartan concentration through 24 hours.
